Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy
Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy
Not yet recruiting · NCT07860814 · Registry updated 2026-10-06Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy | Digestive System Diseases, Fibrosis, Pathologic Processes, Pathological Conditions, Signs and Symptoms, fatty liver disease, liver disorder | Not yet recruiting | Not stated | 2026-10-06 | NCT07860814 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Madrigal Pharmaceuticals, Inc. | 9 |
| Radnet Management, Inc. | 1 |
| Siemens Medical Solutions | 5 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| HMI/Campbell | Houston | United States | 1 |
| HMI/Energy Corridor | Houston | United States | 1 |
| HMI/Pearland | Pearland | United States | 1 |